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. Introduction
Campylobacteriosis, usually acquired by the consumption and handling of poultry -is one of the leading causes of gastroenteritis worldwide [1] . The illness is characterized by diarrhea, abdominal cramps, and fever [2] . Although mortality is rare, significant post-infectious sequelae such as Guillain-Barré syndrome, irritable bowel syndrome, and reactive arthritis do occur [3] [4] [5] [6] . The utilization of fluoroquinolones in feed animals to treat illness and promote growth has contributed to increasingly quinolone-resistant Campylobacter strains [7, 8] , complicating the treatment for patients with severe disease and immunocompromised states, especially children [1] .
In Guatemala, diarrhea is the second most common cause of morbidity and mortality in children <5 years of age [9] . Small, community-based studies in Guatemala suggest that Campylobacter is a common cause of diarrhea in children [10, 11] . However, no estimates have been generated for the incidence of campylobacteriosis in Guatemala or for the degree of antimicrobial resistance. Identification of Campylobacter requires specific culturing techniques with micro-aerobic environments [12] , and few laboratories in Guatemala routinely culture for this pathogen.
In this report, cases are characterized and the incidence of laboratory-confirmed campylobacteriosis is estimated from a facility-based surveillance system in Guatemala from 2008 through 2012. Santa Rosa, with a population of 346,590 persons, is one of 22 administrative departments in Guatemala, and it is located in the semi-tropical southern part of the country. Ethnically, the population is 15% Amerindian indigenous [13] . Quetzaltenango, with a population of 789,358 persons, is in the western highlands and has a population that is 62% Amerindian indigenous. Government health facilities include hospitals, health centers staffed by a physician and nurses, and health posts staffed by nurses. In both surveillance sites, the facilitybased system includes a hospital and an ambulatory component. In Santa Rosa, the surveillance system includes the regional hospital in Cuilapa, the municipal capital of Santa Rosa, as well as the health center and five health posts of the municipality of Nueva Santa Rosa, located 30 km north of Cuilapa. In Quetzaltenango, surveillance includes the regional hospital in the capital of Quetzaltenango, as well as the three health centers and one health post in the municipalities around the capital. In this analysis, the health centers and health posts were collectively considered ambulatory care facilities, and cases captured in these facilities were used for ambulatory surveillance. Data were included from Santa Rosa between January 2008 and August 2012, and from Quetzaltenango between February 2009 and August 2012.
Methods

Study sites
Case detection and data collection
A case of diarrhea was defined as P3 loose or liquid stools in a 24-h period with onset within the seven days preceding presentation to any participating facility by a patient residing in a municipality covered by the surveillance system. To avoid enrolling patients with chronic diarrhea, subjects were excluded if they had any signs or symptoms of diarrhea within the seven days prior to the onset of the current illness. Surveillance nurses screened patients by reviewing log book entries and assessing chief complaints for diarrhea-related visits and admissions. These patients were interviewed, and if found to meet the case definition, detailed clinical, epidemiologic, demographic, and socioeconomic data were obtained through structured patient interviews and medical chart abstractions [14] . In the ambulatory setting, facilities were staffed with surveillance nurses during all working hours and all patients presenting with diarrhea were screened for eligibility. In the hospital setting, except for holidays, surveillance nurses were on-duty seven days per week from 8:00 AM to 5:00 PM. Only patients who were admitted to the hospital were screened for eligibility. This insured that only severe cases of diarrhea were enrolled in hospital surveillance, and it also was the only feasible approach since surveillance nurses were not able to collect all the necessary laboratory and epidemiologic data from patients in the emergency department (ED) before they were discharged.
Laboratory methods
A stool specimen was requested of all consenting patients. For children <5 years of age who were unable to produce a specimen, a rectal swab was collected and placed in Cary-Blair transport media. Stool samples from the ambulatory facilities were stored in Cary-Blair transport media in an insulated cooler at 4°C, and transported within 24 h to one of the two regional hospitals for initial processing and testing. Samples were streaked by direct plating onto Campylobacter selective agar base, Karmali (Oxoid, Basingstoke, UK) and incubated at 42°C for 48 h under microaerophilic conditions provided by the CampyGen TM Generating System (Oxoid, Basingstoke, UK). Small, gray, moist, and flat spreading colonies were considered suspicious of Campylobacter, and were placed on a stained slide for microscopic examination. On visual examination, colonies with ''gull-winged,'' spiral, or ''S''-shaped structures were considered microscopically suspect colonies, and were subsequently plated on Mueller Hinton (Oxoid, Basingstoke, UK) or blood agar and tested with oxidase and catalase and the Dryspot Campylobacter test kit (Oxoid, Basingstoke, UK) to confirm Campylobacter. The hippurate test was used to identify C. jejuni [15] . A specimen was considered negative for Campylobacter if no suspicious colonies grew after 72 h of incubation. Isolates were sent to UVG laboratories for Campylobacter and C. jejuni confirmation and antimicrobial susceptibility testing. Due to limited supplies, antimicrobial susceptibility testing was performed on all cultures done from 2010 to 2011 that grew Campylobacter, using minimum inhibitory concentrations (MIC) via EtestÒ (Biomérieux, Marcy lÕEtoile, France) for the following antimicrobial agents: nalidixic acid (NA), chloramphenicol, ciprofloxacin, erythromycin, and tetracycline [16] . Multidrug-resistance (MDR) was defined as resistance to at least one antimicrobial in at least three of the following antimicrobial groups: macrolides, quinolones, phenicol, and tetracycline [17, 18] .
Data analysis
The number of laboratory-confirmed Campylobacter infections was examined by quarter and stratified by ambulatory and hospital settings separately for Santa Rosa and Quetzaltenango. The total number of diarrhea cases that were captured by the surveillance system was also displayed per quarter. Seasonality of Campylobacter infections was assessed visually using time series graphs.
Annual crude rates for Campylobacter were calculated. Population denominators were obtained for the catchment area of the surveillance facilities by healthcare setting for all ages and for children <5 years, from 2000 through 2010 municipality data from GuatemalaÕs National Institute of Statistics (INE) [13] . Population estimates for the catchment areas in 2011 and 2012 were generated by calculating the average change in municipality population by age from 2009 to 2010, then assuming that same change for 2011 and 2012.
Demographic and clinical characteristics of case-patients treated at ambulatory and hospital settings were compared using chi square tests. Fish-erÕs exact tests were used when cell sizes had counts of five or less. Demographic, geographic, healthcare setting, and clinical differences were explored between patients who had antimicrobial susceptibility data versus those who did not using chi square tests. The proportion resistant was calculated for each of the five tested antimicrobials for all Campylobacter and the subset of C. jejuni. In addition, the difference was tested in the proportion of isolates that were MDR from ambulatory versus hospital settings using FisherÕs exact test.
Ethics
The surveillance protocol was approved by the institutional review boards of the CDC and the UVG, and approved by the Guatemalan MSPAS. Verbal consent was requested of patients in order to screen them for eligibility. Written, informed consent was obtained from eligible patients who were willing to participate. For patients <18 years of age, parents or guardians were asked to provide written, informed consent for the participation of the patient. In addition, children aged 7 through 17 were asked for written, informed assent.
Results
During the five-year analysis period in Santa Rosa, 4327 patients met the case definition for diarrhea and all but one consented to participate; 246 (6.3%) of 3929 (90.8%) stool specimens collected yielded cultures positive for Campylobacter. (Table 2) .
During the study period, the number of laboratory-confirmed Campylobacter infections and diarrhea cases captured by the surveillance system per quarter varied, especially for Santa Rosa (Fig. 1a  and b ). In Santa Rosa, the median proportion of cases with a confirmed Campylobacter infection per stool culture performed per quarter was 8.0% (range, 0.4-17.1%) in the ambulatory setting and 4.1% (range, 0-11.1%) in the hospital setting. In Quetzaltenango, the median proportion was 3.9% (range, 0-13.5%) in the ambulatory setting and 5.0% (range, 0-15.8%) in the hospital setting. The proportion of cases presenting to ambulatory versus hospital settings was higher for both Santa Rosa (86.6%) and Quetzaltenango (73.3%).
Over 40% of the Campylobacter infections occurred in children <1 year of age, over 90% in children <5 years (<50% of patients screened were <5 years of age) ( Table 2 ). More patients presenting to the ambulatory versus hospital settings stated that they had abdominal pain or cramping (p = 0.0002). Over 40% of hospitalized versus 17.0% of ambulatory case-patients had an axillary temperature of P38°C (p = 0.0002). A higher proportion of hospitalized case-patients showed signs (Table 2 ). In the ambulatory setting, 152 patients (66.7%) received or were prescribed oral rehydration solution. Of the 76 patients who did not receive oral rehydration solution in the ambulatory setting, 64 (84.2%) were <5 years of age and 22 (34.4%) of them had sunken eyes, very dry mucosa, delayed capillary refill, or decreased skin turgor (data not shown). In the ambulatory setting, most patients (75.5%) received or were prescribed empiric therapy with metronidazole or trimethoprim-sulfamethoxazole. No patients died. Antimicrobial susceptibility testing was performed on 96 (31.4%) of the 306 laboratory-confirmed Campylobacter case isolates; there were no demographic, geographic, healthcare setting, or clinical differences between patients with and patients without antimicrobial susceptibility data.
Most specimens were C. jejuni (67.7%). Chloramphenicol had the lowest resistance rates while the quinolones including nalidixic acid and ciprofloxacin had the highest (Table 3) . A total of 83 (86.4%) isolates were resistant to at least one antimicrobial class and 12 (12.5%) were MDR (Table 4 ). There was no difference in the proportion of isolates that were MDR in ambulatory versus hospital settings (p = 0.44); 9 (75.0%) of the 12 macrolideresistant strains were MDR (data not shown).
Santa Rosa
Discussion
This study is the first large study to describe laboratory-confirmed Campylobacter infections in Guatemala. In the ambulatory setting in Santa Rosa in 2010, crude annual incidence rates were as high as 215.8 per 100,000 for all ages, and 1288.8 per 100,000 in children <5 years old. Campylobacter primarily affected children <5 years of age, and most patients presented to ambulatory care centers for treatment. Among isolates tested, the proportion that was MDR was 12.5%. In 2009 and 2010 the incidence of Campylobacter infections in the United States reported by FoodNet, which provides population-based estimates of laboratory-confirmed infections commonly transmitted through food from 10 sites, was 13.0 and 13.6 per 100,000 persons, respectively, for all ages [19, 20] . In the ambulatory setting in Santa Rosa, crude incidence rates for all ages in 2009 and 2010 were 10-fold higher than corresponding rates in the United States in 2009 and 16-fold higher for 2010. For the United States in 2010, FoodNet reported the incidence among children <5 years old of 24.4 per 100,000 persons, while in Santa Rosa during that year, this study found an incidence of 1288.8 -over 50-fold greater [19] . The reported incidence rates in other parts of the world varied, including 400 per 100,000 persons in New Zealand (2003) [21] , >120 per 100,000 in Australia (2005) [22] , 44.1 per 100,000 in Europe (2008) [23] , and 30 per 100,000 in Canada (2004) [24] . Rates from Quetzaltenango, Guatemala were lower than Santa Rosa. It is important to note that differences in the surveillance methodology may impact incidence rates.
Quinolone-resistant Campylobacter strains have been rising worldwide in the past two decades [1, 6] . The proportion of Campylobacter isolates resistant to ciprofloxacin in the U.S. National Antimicrobial Resistance Monitoring System (NARMS) in 2010 was 22.4% [17] . In Finland (2003) (2004) (2005) , 45% of Campylobacter strains were resistant to ciprofloxacin [18] . In SENTRY, a worldwide laboratory surveillance network, 42.6% of Campylobacter strains from 10 medical centers in Latin America and 20 in Europe were resistant to ciprofloxacin in 2003 [25] . The data from this study, from April 2010 through December 2011, show an even higher proportion of ciprofloxacinresistance of 59.4%. In addition, whereas 2.1% of isolates reported in NARMS in 2010 were MDR, this study found 12.5% of isolates from the Guatemalan surveillance system to be MDR. Macrolide resistance prevalence in the U.S. has been low (63%) and steady over the past ten years. In Guatemala, resistance prevalence was fourfold (12.5%) higher compared with NARMS. Similar to Finnish data [18] , strains that were macrolide-resistant tended to be MDR.
Although most Campylobacter infections are self-limited and do not require antimicrobial therapy, patients with severe infections, and those who are immunocompromised or pregnant may require antimicrobial treatment. This studyÕs data suggest that resistant strains of Campylobacter are prevalent, making antimicrobial agent selection difficult. In the sentinel sites in Guatemala, >75% of patients in the ambulatory setting received metronidazole or trimethoprim-sulfamethoxazole, neither of which is effective against Campylobacter. At the same time, one-third of patients in the outpatient setting was not prescribed or did not receive oral rehydration solution. Of those, 84.2% were children <5 years of age. One-third of those patients <5 years of age who had not received oral rehydration solution had at least one sign of dehydration on physical exam. These findings highlight the need to reemphasize the adequate training and performance monitoring of proper oral rehydration solution administration, especially among young vulnerable populations.
Similar to the geographic variation in campylobacteriosis in FoodNet sites in the U.S. [26] , this study also found large differences in the rates of Campylobacter infections and the number of patients presenting with diarrhea in Santa Rosa and Quetzaltenango. The warm climate of Santa Rosa likely contributes to the higher rate of diarrheal disease in the department [27] . Differences in healthcare seeking behaviors and hospital admitting practices may also partially explain the difference. In the United States, campylobacteriosis is a seasonal disease that peaks in the summer months [26] . In Guatemala, a definitive seasonal pattern was not observed, perhaps because temperatures remain relatively stable throughout the year. The findings of this study are subject to a number of limitations. Although the surveillance platform includes most of the government facilities in the populations studied, not all patients seek care in these facilities and some do not seek care at all. Therefore, the crude incidence rates are an underestimate of the true incidence of Campylobacter disease. In addition, surveillance in the hospital setting only includes patients who are admitted. Thus, patients seen in the ED and then discharged or transferred will not be included in this data, again leading to underestimates in the rate calculations. The presence of Campylobacter in healthy controls was not tested to determine what proportion of the cases identified in this surveillance system may have been asymptomatic carriers of Campylobacter whose disease was caused by another enteric pathogen. Finally, these data are from the departments of Santa Rosa and Quetzaltenango and therefore may not be generalizable to all of Guatemala. These data, however, are the most comprehensive description of campylobacteriosis in Guatemala and Central America in the healthcare setting.
Conclusion
Campylobacter is a major cause of diarrhea in children <5 years of age in Guatemala with disease rates in the ambulatory setting significantly higher than those of the United States. Consistent with the epidemiology of Campylobacter elsewhere, disease predominantly affected younger age groups. Similar to FoodNet data from the United States, rates varied substantially between sites, but unlike FoodNet, no seasonal pattern was apparent. Although treatment is normally supportive, one-third of patients in the outpatient setting was not prescribed or given oral rehydration therapy and >75% were given an antimicrobial ineffective against Campylobacter. Quinolone-resistant and MDR Campylobacter proportions were higher in Guatemala than in other countries, potentially complicating the treatment for immunocompromised and pregnant patients or those with severe disease. This study illustrates the capacity of a sentinel healthcare facility-based surveillance system to provide working estimates of the incidence of an acute infectious disease. The next steps in addressing the burden of campylobacteriosis in Guatemala include the utilization of this platform to identify risk factors for Campylobacter infection through focused case-control studies; test interventions based on results of risk-factor studies, aimed at reducing the burden of disease; identify optimal treatment regimens for diarrhea in these populations; and establish the further burden of post-infectious sequelae of campylobacteriosis and the economic cost of the illness.
